This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis C. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis C.
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
The Epidemic Intelligence Information System (EPIS) is a web-based communication platform that allows nominated public health experts to exchange technical information to assess whether current and emerging public health threats have a potential impact in the European Union (EU).
This key provides the non-specialist with reference material to help recognise an invasive mosquito species and gives details on the morphology to help with verification.
This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA.
This reporting protocol is intended for reporting national case-based data for surveillance of hepatitis of unknown origin from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA), to the European level.
This document provides guidance on diagnostic testing, molecular characterisation and metagenomic analysis for suspect cases of severe acute hepatitis of unknown aetiology.